481 Results (Page 9 of 20)
UK Markets Research Reports
UK Transthyretin Amyloidosis (ATTR) Market Analysis
UK Transthyretin Amyloidosis (ATTR) Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Transthyretin Amyloidosis (ATTR) market is growing globally due to the increase in disease awareness, advancements in diagnostic techniques, development of disease-modifying therapies, growing investment in research and development, regulatory support and expedited approvals, collaboration and partnerships between pharmaceutical companies and academic institutions. Pfizer Inc, AstraZeneca, Prothena Corporation plc, Ionis Pharmaceuticals, BELLUS Health Inc , Alnylam Pharmaceuticals, Inc, Eidos Therapeutics, Inc, SOM BIOTECH, Abbvie, Inc., Bausch Health Companies Inc., Bristol Myers Squibb Company, GSK Plc. are the key global market players in transthyretin amyloidosis (ATTR) market.
UK Type 1 Diabetes Mellitus Drugs Market Analysis
UK Type 1 Diabetes Mellitus Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Type 1 Diabetes Mellitus Drugs market is growing globally due to the rising prevalence of type 1 diabetes mellitus, advancements in insulin therapies, technological advancements in insulin delivery systems, increasing focus on personalized medicine, rising healthcare expenditure, favorable reimbursement policies, increasing patient awareness and education, research and development initiatives and collaborations between pharmaceutical companies and academic institutions. Novo Nordisk, Eli Lilly and Company, Sanofi, Medtronic, Abbott Laboratories, Dexcom, Zealand Pharma, Xeris Pharmaceuticals, Insulet Corporation, and Tandem Diabetes Care are the key global market players in type 1 diabetes mellitus drugs market.
UK Type 2 Diabetes Mellitus Drugs Market Analysis
UK Type 2 Diabetes Mellitus Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Type 2 Diabetes Mellitus Drugs market is growing globally due to the increasing prevalence of Type 2 diabetes, growing awareness and diagnosis about the disease, advancements in drug therapies, rising geriatric population, government initiatives and healthcare policies, technological advancements in drug delivery, increasing research and development activities and rising healthcare infrastructure. Novo Nordisk, Sanofi, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Johnson & Johnson, Boehringer Ingelheim, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb, Novartis International are the key global market players in type 2 Diabetes Mellitus Drugs Market.
UK Tyrosine Kinase Inhibitors Market Analysis
UK Tyrosine Kinase Inhibitors Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Tyrosine Kinase Inhibitors market is growing globally due to the Increasing prevalence of cancer, increasing use instead of conventional medicines due to their benefits, including the simplicity of oral administration, the capacity to target various cellular survival pathways, and the surge in demand for novel medications. The market is also influenced by an increase in pharmaceutical company investment and the utilization of cell processes to control different cell activities in cancer. Additionally, the market for tyrosine kinase inhibitors is positively impacted by increase in healthcare spending, awareness, population growth, increased healthcare infrastructure, and improvements in cancer treatments. F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Ascentage Pharma, AstraZeneca, Eisai Co., Ltd., Novartis AG, Sanofi, Bristol-Myers Squibb Company, Genentech, Inc., Pfizer Inc., Merck & Co., Inc., Suzhou Zelgen Biopharmaceuticals Co., Ltd., Celldex Therapeutics, Exelixis, Inc., Sino Biological Inc., AB Science, Bayer AG Deciphera Pharmaceuticals, Inc., and Johnson & Johnson Services, Inc are the key global market players in tyrosine kinase inhibitors market.
UK Ulcerative Colitis Market Analysis
UK Ulcerative Colitis Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Ulcerative Colitis market is growing globally due to the increasing prevalence of ulcerative colitis, advancements in treatment options like introduction of biologic therapies, such as anti-TNF agents, anti-integrin agents and JAK inhibitors, rising awareness and diagnosis about disease, personalized medicine approaches, research and development initiatives, collaborations and partnerships between pharmaceutical companies and academic institutions. Johnson and Johnson, AbbVie Inc. (Allergan, Inc.), Merck & Co., Inc., Novartis AG, Bausch Health Companies Inc. are the key global market players in ulcerative colitis market.
UK Unresectable Hepatocellular Carcinoma Market Analysis
UK Unresectable Hepatocellular Carcinoma Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Unresectable Hepatocellular Carcinoma market is growing globally due to the increasing incidence of unresectable hepatocellular carcinoma which is mainly due to rise in risk factors such as chronic hepatitis B and C infections, alcohol abuse, non-alcoholic fatty liver disease (NAFLD), and obesity. Advancements in diagnostic techniques like imaging techniques and biopsy, introduction of targeted therapies, immunotherapies, rising emphasis on combination therapies, clinical Trials and research initiatives. Bayer AG, Bristol Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Ipsen Pharma, Merck & Co., Inc., Novartis International AG, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited are the key global market players in unresectable hepatocellular carcinoma market.
UK Urothelial Carcinoma Market Analysis
UK Urothelial Carcinoma Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Urothelial Carcinoma market is growing globally due to the increasing incidence and prevalence of urothelial carcinoma due to aging population, smoking, exposure to certain chemicals, and chronic bladder inflammation, advancements in diagnostic techniques like urinary biomarkers, cystoscopy, development of novel therapies like targeted therapies or immune checkpoint inhibitors and increased focus on personalized medicine. AstraZeneca PLC, Bristol Myers Squibb Company, Eli Lilly and Company, Genentech, Inc. (a member of the Roche Group), Merck & Co., Inc., Novartis AG, Pfizer Inc., Seattle Genetics, Inc., Sanofi S.A., Johnson & Johnson are the key global market players in urothelial carcinoma market.
UK Varicella Vaccine Market Analysis
UK Varicella Vaccine Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Varicella Vaccine market is growing globally due to the increasing vaccination coverage, growing public awareness about varicella vaccination, well established safety and efficacy profile of varicella vaccine, launch of varicella control programs by various governments. Merck & Co., Inc., GlaxoSmithKline plc, Sanofi Pasteur, Pfizer Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech International Ltd., Changchun BCHT Biotechnology Co., Ltd., Sinovac Biotech Ltd., Kaketsuken (Japan Blood Products Organization) and Shanghai Institute of Biological Products are the key global market players.
UK Viscosupplementation Market Analysis
UK Viscosupplementation Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Viscosupplementation market is growing globally due to the increasing prevalence of osteoarthritis, growing aging population, and rising awareness about minimally invasive treatment options, increasing awareness and acceptance, technological advancements in viscosupplementation treatments, rise in the healthcare sector spending and infrastructure. Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Bioventus, Fidia Farmaceutici S.P.A, Ferring B.V, sanofi-aventis U.S. LLC, Zimmer Biomet, OrthogenRx, Inc. (a subsidiary of AVNS), APTISSEN, Johnson & Johnson Services, Inc., LG Chem., Viatris Inc., IBSA Institut Biochimique SA, Ortobrand International, TRB CHEMEDICA SA, Teva Pharmaceutical Industries Ltd., Lifecore (a subsidiary of Landec Corporation), VIRCHOW are the key global market players of viscosupplementation market.
UK Vision Care Market Analysis
UK Vision Care Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Vision Care market is growing globally due to the increasing prevalence of eye disorders such as myopia, hyperopia, astigmatism, and age-related macular degeneration (AMD), surging volume of patients suffering from chronic diseases which will led to the occurrences of vision ailments, improper intake of nutrition and unhealthy food eating habits, technological advancements in vision care industry like innovations in lens materials, frame designs, and contact lens technologies, increasing awareness about the importance of regular eye exams and eye health initiatives by governments, healthcare organizations and growth of the e-commerce sector. EssilorLuxottica, Johnson & Johnson, Novartis AG (Alcon), CooperVision, Bausch Health Companies (Bausch + Lomb), Zeiss, Hoya Corporation, Safilo Group and Carl Zeiss Meditec are the key global market players.
UK Wearable Injectors Market Analysis
UK Wearable Injectors Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Wearable Injectors market is growing globally due to the strong healthcare infrastructure, rise in the incidence of lifestyle disorders, an ageing population that is more susceptible to diseases, increase in the desire for minimally invasive (MI) treatment alternatives, rise in chronic diseases like diabetes, autoimmune diseases, patient preference for self-administration medications in the comfort of their homes which enhances patient convenience, improves medication adherence, technological advancements in wearable injector technology which have improved device usability, functionality, patient experience. Continuous drug delivery provided by wearable injectors like more stable drug levels, reduced fluctuations, focus on patient centric care and cost-effective solutions provided by wearable injectors. Medtronic plc, Insulet Corporation, West Pharmaceutical Services, Inc., Enable Injections, SteadyMed Therapeutics, Inc., Sensile Medical AG, CeQur SA, Ypsomed AG, Becton, Dickinson and Company and Tandem Diabetes Care, Inc. are the key global market players in wearable injectors market.
UK Alopecia Drugs (Hair Loss) Market Analysis
UK alopecia drugs (hair loss) market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising prevalence of alopecia, rising awareness and consciousness among individuals about their appearance, and the development of advanced treatment technologies. Johnson & Johnson, Merck & Co., GlaxoSmithKline plc, Cipla Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Histogen Inc., Aclaris Therapeutics, and Concert Pharmaceuticals are the key players in this market.
UK Aminoglycosides Market Analysis
UK Aminoglycosides Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The Aminoglycosides market is a segment of the pharmaceutical industry that focuses on the production and sale of aminoglycoside antibiotics. Key factors driving the market include the increasing prevalence of bacterial infections, especially drug-resistant strains, which require potent antibiotics like aminoglycosides. The growing geriatric population and the rise in chronic diseases also contribute to the demand for aminoglycosides. The market analysis also considers restraints such as the potential side effects and toxicity associated with aminoglycoside use. These antibiotics can cause serious adverse effects, including kidney damage and hearing loss, which limit their long-term use. Furthermore, the emergence of alternative antibiotics and the growing concern over antibiotic resistance pose challenges to the market growth. Some of the prominent global players in the Aminoglycosides market include Pfizer Inc., Merck & Co., Inc., Novartis AG, Bristol Myers Squibb Company, Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson, Aurobindo Pharma Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
UK Anti-Aging Drugs Market Analysis
UK Anti-Aging Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The Anti-Aging Drugs market is driven by the increasing aging population, advancements in medical research, growing consumer awareness and beauty standards, and the emphasis on preventive healthcare, prompting individuals to seek effective solutions for maintaining a youthful appearance and improving overall well-being. However, the Anti-Aging Drugs market also faces certain restraints. These include stringent regulatory requirements, potential safety concerns, and ethical considerations associated with the use of anti-aging drugs. Additionally, the high cost of some anti-aging drugs may limit their accessibility to a wider population. The Anti-Aging Drugs market is highly competitive, with several key players contributing to its growth and development. Companies such as Allergan, Galderma, Merz Pharma, and Johnson & Johnson are renowned for their expertise in developing and manufacturing anti-aging drugs and treatments.
UK Anti-Venom Market Analysis
UK Anti-Venom Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Purified antibodies are used to prevent snake venom from attaching to tissues and causing severe allergic reactions, blood clotting, muscular injury, or nervous system difficulties. The anti-venom market is being driven by the rising global incidence of snakebites, which is fueling demand for effective snakebite treatment options such as anti-venom products. Anti-venom awareness and education efforts have been critical in emphasising the necessity of anti-venom in snakebite management. Manufacturing and delivery techniques advancements have enhanced the safety, efficacy, and accessibility of anti-venom medications. However, market obstacles include restricted access in rural places, high manufacturing costs, a lack of specificity and efficacy in particular formulations, and safety concerns about potential adverse responses and difficulties during therapy.Some global players in the anti-venom market include CSL Limited, BTG plc, Merck & Co., Inc., Pfizer Inc., Sanofi Pasteur SA, Haffkine Bio-Pharmaceutical Corporation Ltd., Rare Disease Therapeutics, Inc., Instituto Bioclon, S.A. de C.V., and Bharat Serums and Vaccines Limited.
UK Anticoagulants Market Analysis
UK Anticoagulants Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Anticoagulants, commonly known as blood thinners, reduce the risk of blood clots and related consequences by suppressing the clotting mechanisms in the blood. Increased cardiovascular illnesses, an ageing population, greater awareness, technical improvements, advantageous reimbursement policies, and an increase in surgical operations are driving the anticoagulants market. However, there are hazards of bleeding, regulatory requirements, and generic alternatives. The presence of many prominent companies who play a crucial part in developing the industry characterises the global anticoagulants market. Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Sanofi S.A., Novartis AG, Merck & Co., Inc., and Portola Pharmaceuticals, Inc. are among the prominent participants.
UK Antiepileptics Drugs Market Analysis
UK Antiepileptics Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Epilepsy is a chronic neurological disorder characterized by recurrent seizures. The market for antiepileptic drugs is driven by the growing prevalence of epilepsy worldwide and the continuous need for effective and well-tolerated medications. Continuous advances in drug research and development help to bring new and improved antiepileptic treatments to market. These developments result in the creation of pharmaceuticals with improved efficacy, safety profiles, and fewer side effects, which drives market expansion. Some prominent players in the market include UCB Pharma, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Johnson & Johnson, Sanofi S.A., Eisai Co., Ltd., Sunovion Pharmaceuticals Inc., Cephalon, Inc., and Teva Pharmaceutical Industries Ltd.
UK Antithrombotic Drugs Market Analysis
UK Antithrombotic Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising prevalence of cardiovascular disorders, growing geriatric population, developments in medication research, supportive government initiatives and advantageous reimbursement regulations for antithrombotic drugs drive market expansion. The antithrombotic drugs market is dominated by several key players who play a crucial role in driving advancements in the field of cardiovascular medicine. These key players include renowned pharmaceutical companies such as Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Portola Pharmaceuticals, Inc., AstraZeneca PLC, and Bayer AG.
UK Asthma Drugs Market Analysis
UK Asthma Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for asthma drugs is primarily driven by the increasing prevalence of asthma globally, Growing awareness among patients and healthcare providers about the importance of asthma management and the availability of effective treatment options further fuel market growth. Key players in the asthma drugs market include pharmaceutical companies such as GlaxoSmithKline, Roche, AstraZeneca, Novartis, Merck & Co., and Teva Pharmaceutical Industries.
UK Atherosclerosis Drugs Market Analysis
UK Atherosclerosis Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The atherosclerosis drugs market is driven by factors such as the rising prevalence of cardiovascular diseases, advancements in drug development, and growing awareness about early diagnosis and treatment. The key players in the atherosclerosis drugs market include Pfizer Inc., AstraZeneca PLC, Novartis AG, Bristol-Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Amgen Inc., Eli Lilly and Company, Bayer AG, and GlaxoSmithKline PLC.
UK Atopic Dermatitis Drugs Market Analysis
UK Atopic Dermatitis Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for atopic dermatitis drugs is driven by the increasing prevalence of the condition, especially among children, leading to a demand for effective treatments. Some of the prominent players in the market include Pfizer Inc., Sanofi SA, Novartis AG, Regeneron Pharmaceuticals Inc., Galderma S.A., Leo Pharma A/S, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, and Johnson & Johnson.
UK Autologous Matrix-induced Chondrogenesis Market Analysis
UK Autologous Matrix-induced Chondrogenesis Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The AMIC market is driven by increasing knee injuries and cartilage defects, advancements in regenerative medicine, and the growing geriatric population. However, limited awareness and high costs are restraints. Ongoing research, collaborations, and investments are expected to address restraints and drive further advancements in the AMIC market. Key players globally in AMIC market are Geistlich Pharma AG, Arthrex, Zimmer Biomet Holdings, Smith & Nephew plc, Vericel Corporation, and B. Braun Melsungen AG, among others.
UK Axial Spondyloarthritis (axSpA) Market Analysis
UK Axial Spondyloarthritis (axSpA) Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. With ongoing research and development efforts, the expansion of treatment options, and increasing patient awareness, the axSpA market is expected to witness significant growth in the coming years. AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co., UCB S.A., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH are the global key players in axSpA market.
UK Biological Safety Testing Market Analysis
UK Biological safety testing Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The biological safety testing market is driven by increasing demand for biologics, stringent regulatory requirements, rising incidence of infectious diseases, technological advancements, and growth in the biotechnology and pharmaceutical industries. Charles River Laboratories International, Merck KGaA, Lonza Group Ltd., Eurofins Scientific, SGS SA, WuXi AppTec, Toxikon Corporation, Avista Pharma Solutions, Nelson Laboratories, Pace Analytical Services are among the global key players.
UK Biosimilar Monoclonal Antibodies Market Analysis
UK Biosimilar Monoclonal Antibodies Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Market drivers for biosimilar monoclonal antibodies include rising demand for low-cost biologics, the increasing frequency of chronic diseases, and the need for more economical biologic therapeutics. Among the key global pharmaceutical companies in the Biosimilar Monoclonal Antibodies Market are Samsung Bioepis Co., Celltrion Inc., Biocon Ltd., Pfizer Inc., Amgen Inc., Novartis AG (Sandoz), Mylan N.V., Boehringer Ingelheim International GmbH, Fresenius Kabi AG, and Teva Pharmaceutical Industries Ltd.